- Previous Close
0.9500 - Open
0.9200 - Bid --
- Ask --
- Day's Range
0.9020 - 0.9960 - 52 Week Range
0.8200 - 3.9200 - Volume
11,536 - Avg. Volume
130,501 - Market Cap (intraday)
2.987M - Beta (5Y Monthly) -0.17
- PE Ratio (TTM)
7.53 - EPS (TTM)
0.1200 - Earnings Date May 14, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.02
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
www.xortx.comRecent News: XRTX
View MorePerformance Overview: XRTX
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XRTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XRTX
View MoreValuation Measures
Market Cap
3.18M
Enterprise Value
936.74k
Trailing P/E
8.00
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.45
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.21%
Return on Equity (ttm)
-83.06%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-3.31M
Diluted EPS (ttm)
0.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
2.47M
Total Debt/Equity (mrq)
1.16%
Levered Free Cash Flow (ttm)
-1.11M